Investor Presentaiton

Investor presentation Full year 2018 Slide 89 SaxendaⓇ has rapidly grown value market share, but market development efforts are required to expand the market Despite strong SaxendaⓇ growth, US obesity care market remains small at around USD 839 million Generic AOM Novo Nordisk is investing in overcoming the barriers preventing effective obesity care Current state Key initiatives SaxendaⓇ Other branded AOM TRX SU market share mUSD/value market share 100 900 90 800 6% Mindset 80 700 70 36% 600 60 83% 500 50 400 Few prescribers engaged 40 300 30 58% 20 10 13% 200 100 Limited patient access 4% Volume Value AOM: Anti-obesity medication; TRx standard units Volume Source: IQVIA NPA moving annual total through Nov 2018; NSP moving annual total through Nov 2018 changing diabetes Acute weight loss focus with SaxendaⓇ stay- time ~5 months Advocate for chronic treatment through partnerships Less than 3,000 physicians write ≥10 AOM prescriptions per month Only 2 in 5 of ~95 million adults with obesity have access to reimbursed medication Launch obesity educator programme Obtain Medicare coverage through support of "Treat and Reduce Obesity Act" novo nordisk

View entire presentation